• Loss for the half-year up 47.3% to $2.72 million
• Continued focus on building commercial business and product development
• Expanded distribution and regulatory approvals in Asia-Pacific markets

ReNerve Limited reported a 47.3% increase in loss for the half-year ended 31 December 2025 to $2.72 million, compared to $1.84 million in the prior corresponding period. The company remains focused on building a portfolio of regenerative biological-based tissue products for the repair and replacement of injured peripheral nerves and related surgical procedures. Over the past year, ReNerve has expanded its commercial products with the launch of the Empliq range, which complement the existing NervAlign® product lines. The company has also increased its activities in non-US markets, obtaining approvals in Hong Kong and Malaysia for its NervAlign® Nerve Cuff. To support the growth of the nerve repair business, ReNerve continues to work with surgeons to confirm the unique characteristics of the NervAlign® Nerve Cuff. The company also entered a strategic partnership with Berkeley Biologics in June 2025 to commercialize two tissue-based product ranges. During the period, ReNerve progressed its commercial development programs with partners on the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix products. The company also completed a $3.2 million capital raise in December 2025 to support accelerated sales and marketing activities, product launches, and overall growth initiatives.